Bortezomib
Navigation Links
Bortezomib in Medical News
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evalu...... multiple myeloma patients previously treated with bortezomib (VELCADE((R))). The SPA provides agreement that t...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre... safety of KRX-0401 vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, wil...
... Phase I study of elotuzumab (HuLuc63) in combination with bortezomib in relapsed multiple myeloma Lead investigator: Andrzej Jakubo...30 pm ET Panobinostat & bortezomib phase I trial in multiple myeloma Lead investigator: Orhan Se...
Green tea may negate the effects of a common cancer therapy
...ract the anticancer effects of one cancer therapy, bortezomib (Velcade ), and may be contraindicated for pati...valuated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, ...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteas...Green Tea May Negate the Effects of a Common Cancer Therapy
...ract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patie...evaluated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, a...d to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteaso...Cancer drug effectively treats transplant rejections
...ge role in the humoral immune response by making immune proteins that attack transplanted organs. "We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory," says Woodle, lead author of the study and chief of transplant surgery at UC. "Moreo......2 Clinical Trial of Perifosine in combination with bortezomib (+/- dexamethasone) on Tuesday, December 9, 2008 a... of a Multicenter Trial of Perifosine (KRX-0401) + bortezomib in Patients with Relapsed or Relapsed / Refractory...btained to date on the combination of KRX-0401 and bortezomib in relapsed and refractory multiple myeloma patien...
VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients
...interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinos...sess whether patients who have previously received bortezomib respond differently from those who have never been treated with bortezomib. bortezomib administered alone has recently been approved for ...Combination Therapy Helps to Combat Myeloma
...at preclude them from receiving high doses of the standard drug therapies melphalan and prednisone, or a transplant, experts said. "The addition of bortezomib (Velcade) resulted in significant prolongation in time to disease progression with a reduction of 52 percent in risk of progression," said lead resear......A(1) trial showed 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit," said Paul Ri...ur days every 6 weeks or the same MP schedule with bortezomib (1.3 mg/m2) IV on days 1, 4, 8, 11, 22, 25, 29 and...
Bortezomib in Medical Technology
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression
NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...
- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers - ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from an ongoing randomiz...
...57 induces an anti-inflammatory response at doses less than one tenth the Maximum Tolerated Dose (MTD). In contrast, nonselective inhibitors, such as bortezomib and carfilzomib, induce anti-inflammatory responses only at or near their MTD. These findings also underline the key role played by the immunoproteas...
...tients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and wer...ase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly amo...
... Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -...ivity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refr...
...6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II ...
...to evaluate patients' overall response rate after four cycles of carfilzomib. All patients enrolled in the trial have received prior treatment(s) with bortezomib and either lenalidomide or thalidomide and are refractory to their last treatment. A second open-label, multi-center Phase 2 trial of single-agent c...
- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers - ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from an ongoing randomiz...
...57 induces an anti-inflammatory response at doses less than one tenth the Maximum Tolerated Dose (MTD). In contrast, nonselective inhibitors, such as bortezomib and carfilzomib, induce anti-inflammatory responses only at or near their MTD. These findings also underline the key role played by the immunoproteas...
...tients enrolled in the Phase 2 trial have relapsed following treatment with bortezomib and an immunomodulatory agent, such as thalidomide or lenalidomide, and wer...ase 2 clinical trial designed to evaluate response rates based on patients' bortezomib treatment history demonstrated substantial response rates, particularly amo...
... Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -...ivity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refr...
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
...cer Centers-Parker: Results of a Phase II study of bortezomib in patients with relapsed or refractory indolent l...ncer Centers-Midtown: Phase II open label-trial of bortezomib in patients with multiple myeloma who have undergo... Centers-Midtown: Phase II trial of combination of bortezomib and Rituximab in relapsed and/or refractory Walden......6:00 p.m. -- 8:00 p.m. PST Session: Molecular Pharmacology, Drug Resistance Poster II -- Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) Session: Myeloma -- Pathophysiology and Preclinical Studies Excluding Therapy Poster II ...
Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
.... Telik's proteasome inhibitors are orally active, non-peptide, non-boron based, and thus may lead to a drug candidate that might have advantages over bortezomib and other proteasome inhibitors. "The potentially favorable profile of these compounds was achieved through the use of our TRAP(R) computational dru......to evaluate patients' overall response rate after four cycles of carfilzomib. All patients enrolled in the trial have received prior treatment(s) with bortezomib and either lenalidomide or thalidomide and are refractory to their last treatment. A second open-label, multi-center Phase 2 trial of single-agent c...
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
...and helping patients fight cancer." Data from the following studies will be presented: -- The Effect of Pegylated Liposomal Doxorubicin Plus bortezomib in Multiple Myeloma Patients with Renal Insufficiency (Abstract 8562) Presentation: Saturday, May 31, 8:00 am - 12:00 pm CST, General ...Bortezomib in Biological News
Massey researchers induce cell death in leukemia
...or of translational research, interactions between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporati...ed in human CLL cells isolated from five patients. bortezomib dramatically potentiated the lethality of both age...An AIDS-related virus tricks cells to become tumors, new Penn study finds
...n be free to activate genes involved in growth of blood vessels to increase the blood supply to the tumor. "Use of such proteosome inhibitors as bortezomib as cancer therapeutic agents has been ongoing for the last four to five years and this study provides crucial step in understanding the mechanism for ...Compound from marine bacteria shows potential as multiple myeloma therapy
...teasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of comp... Though less toxic than conventional chemotherapy, bortezomib does have significant side effects in some myeloma...e resistant to bortezomib. Because NPI-0052 and bortezomib attack the same intracellular target in different ...Bortezomib in Biological Technology
... multiple myeloma patients previously treated with bortezomib (VELCADE(R)). The SPA provides agreement that the ...d Safety of Perifosine Added to the Combination of bortezomib and Dexamethasone in Multiple Myeloma Patients Pre...afety of perifosine vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will...
...l cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global biopharmaceutical compan...
...al trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rat...s not been reached. Among patients with prior bortezomib exposure, 18 percent achieved partial responses an...
...tation and posters: Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level...
...Activity in Relapsed Patients by Prior Exposure to bortezomib A second presentation by Dr. Vij described...gned to evaluate response rates based on patients' bortezomib treatment history. Patients enrolled in this tria...: Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) and The Selective...
...lecules for the enzymatic removal of ubiquitin markers in incorrectly folded proteins. The inventions also protect the use of the proteasome inhibitor bortezomib (Velcade (R)) for second medical use in cystic fibrosis (Velcade (R) has already been approved for use in humans to treat other indications). For ...
...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...
...l cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global biopharmaceutical compan...
...al trial to date, of which 45 percent had no prior bortezomib experience and 55 percent relapsed following bortezomib treatment. In both arms, substantial response rat...s not been reached. Among patients with prior bortezomib exposure, 18 percent achieved partial responses an...
...tation and posters: Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM) (Abstract 8591) General Poster Session, Saturday May 30, 8:00 am to 12:00 pm, Level...
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
...trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. In addition, results from a Phase Ib/II study of carfilzomib in p......Activity in Relapsed Patients by Prior Exposure to bortezomib A second presentation by Dr. Vij described...gned to evaluate response rates based on patients' bortezomib treatment history. Patients enrolled in this tria...: Non-Proteasomal Targets of Proteasome Inhibitors bortezomib and Carfilzomib (Abstract #2657) and The Selective...
...lecules for the enzymatic removal of ubiquitin markers in incorrectly folded proteins. The inventions also protect the use of the proteasome inhibitor bortezomib (Velcade (R)) for second medical use in cystic fibrosis (Velcade (R) has already been approved for use in humans to treat other indications). For ...
Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas......echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...
Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
...echanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breas...Bortezomib in Biological Dictionary
...easome , COP9 signalosome and related complexes) ... Proteasome , COP9 signalosome, TPPII ... Proteasome inhibitor drug for treating cancer. ... bortezomib is a highly selective, reversible inhibitor of the 26S proteasome . ... The Proteasome -Glo™ Cell-Based Assays(a,b) are homogeneous, luminescent ...
Other TagsSpeciallyMotionMotionMotionAbnormalitiesIncomeProlactinOther Contentsfunnelfunnelfurniturefurniturefurniturefurniturefurunclegalactosegalactosegalactosemiagalliumgallbladdergallbladdergallbladder
VandetanibSpeciallySrinagarGrosslyDiscreditedMozambiqueMotionStandardizedAbnormalitiesTanzaniaAnoushkaIndonesiansIncomeProlactin
(Date:11/27/2009)... Multi-purpose bilingual coloring books ...se by the business community to educate - inform p... from Safety issues to Dinosuars to ABC,S and a ho...nt Louis, MO (PRWEB) November 27, 2009 -- Today&rs... toys to keep them busy any hour of the day, but o...
(Date:11/27/2009)... Three new interactive anatomy education...Wilkins expand health sciences learning opportunit... Durham, NC (Vocus) November 27, 2009 -- Mo...s (LWW), a division of Wolters Kluwer Health, toda...education apps on the App Store. Clemente’s ...
(Date:11/26/2009)...ON,N.J.,Nov.27/PRNewswire/--Thediabetespopulationi...andannualmedicalspendingonthediseaseisprojectedtoh...tudypublishedintheDecemberissueof DiabetesCare .Th...ogramofNovoNordisk,commissionedtheanalysisbyateamf...ecast,thenumberofAmericanslivingwithdiabeteswillri...
(Date:11/26/2009)...questering drug tetrathiomolybdate (TM) has been s...f Wilson disease, a disease caused by an overload ...ch is known. Very little, however, is known about ...ew study led by Northwestern University researcher...imensional structure of TM bound to copper-loaded ...
(Date:11/26/2009)...er thrill when on an emotional rollercoaster, stud... News) -- Call it the fear factor meets the jubila...tators -- especially those who root for the winnin...a closely contested match and victory was in doubt..., Chew on that this Thanksgiving weekend as you,r...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3[0] Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books [0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[1] Research sheds light on workings of anti-cancer drug[0] Watching the Nail-Biting Big Game Hurts So Good
(Date:11/23/2009)...ence that the "synergistic" effect of early-life e...and indoor endotoxin causes more harm to developin... Environmental health scientists at the Universit...n that children exposed to both high levels of tra... early life are six times more likely to experienc...
(Date:11/23/2009)...Society says that western lowland gorillas living ...he "mother lode" of more than 125,000 gorillas dis...ned by growing humans activity in the region. , ...ts adjacent to the southwest border of Lac Tl Comm...high densities of the great apes still exist in th...
(Date:11/23/2009)...able for the H1N1 virus has been sent to vaccinate...tion marks the first time vaccine has been sent to...Iowa State University,s Hank Harris, professor of ...and has been shipping preventive doses to swine pr...eeks., The latest vaccines were shipped to a swi...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 1WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 2WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 3WellPoint State Sponsored Business Launches New Program with Arcadia HealthCare to Help Improve Medication Safety Efficacy and Compliance for Medicai 49887 410th CyberKnife System Installed at an HCA Hospital 49885 110th CyberKnife System Installed at an HCA Hospital 49885 210th CyberKnife System Installed at an HCA Hospital 49885 310th CyberKnife System Installed at an HCA Hospital 49885 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 1The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 2The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 5| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |